Switching from Vitamin K Antagonist to Dabigatran in Atrial Fibrillation: Differences According to Dose.

In atrial fibrillation (AF) patients 150mg b.i.d. dabigatran is the standard dose, yet guidelines recommend 110mg b.i.d. when bleeding risk is high. It is unknown to which extend these recommendations are followed in patients switching from vitamin K antagonist (VKA) to dabigatran. The aim of this study was to investigate if AF patients are switched from vitamin K antagonist to the appropriate dose of dabigatran. METHODS Using nationwide registries (Aug 22, 2011-Dec 31, 2012) we identified VKA-experienced AF patients with available creatinine values who switched to dabigatran. European guidelines criteria 2012 on dabigatran dosing were examined: age≥80 years, HAS-BLED≥3, estimated glomerular filtration rate (eGFR)<50mL/min/1.73 m2, or use of interacting drugs. RESULTS We identified 1,626 VKA-experienced AF patients who switched to dabigatran 110mg (820 patients) or 150mg (806 patients). Patients who switched to 110mg compared with 150mg were older (median age 82 years [Q1-Q3:77-86] vs. 68 years [Q1-Q3:64-74]), more often female (54% vs. 35%), had a higher comorbidity burden, higher proportion with CHA2DS2-VASc score≥2 (98% vs. 80%), and more with a HAS-BLED score ≥ 3 (46% vs. 28%). Patients switched to 110mg had a higher absolute risk of mortality compared to patients switched to 150mg. Overall, 26% were inappropriately dosed and 14% were switched to 110mg although the higher dose was indicated. Further, 39% of patients switched to 150mg fulfilled one or more criteria for 110mg, this mostly driven by high HAS-BLED scores (28.2% of patients on 150mg). Female sex, age>80 years, eGFR<50 mL/min/1.73 m2, drugs interacting with dabigatran, and prior bleeding were associated with switch to 110mg. Patients inappropriately dosed had similar risk of mortality as patients appropriately dosed. CONCLUSION Among VKA-experienced AF patients one in four were switched to a dabigatran dose contrary to guideline recommendations.

[1]  L. Køber,et al.  Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013. , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[2]  D. Singer,et al.  Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry. , 2016, Journal of the American College of Cardiology.

[3]  M. Biteker,et al.  PRescriptiOn PattERns of Oral Anticoagulants in Nonvalvular Atrial Fibrillation (PROPER study) , 2017, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[4]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[5]  J. Dogné,et al.  Appropriateness of Prescribing Dabigatran Etexilate and Rivaroxaban in Patients With Nonvalvular Atrial Fibrillation , 2014, The Annals of pharmacotherapy.

[6]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.

[7]  A. Camm,et al.  European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[8]  C. Granger,et al.  Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs , 2015, The Lancet.

[9]  S. Yusuf,et al.  Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial , 2011, Circulation.

[10]  S. Goldhaber,et al.  Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy. , 2016, The American journal of medicine.

[11]  P. Weeke,et al.  Bleeding risk in ‘real world’ patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort , 2011, Journal of thrombosis and haemostasis : JTH.

[12]  D. Fitzmaurice,et al.  Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation: Results From the GARFIELD-AF Registry , 2019, Circulation.

[13]  L. Køber,et al.  Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study , 2013, BMJ Open.

[14]  F R Rosendaal,et al.  A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy , 1993, Thrombosis and Haemostasis.

[15]  G. Lip,et al.  Patient outcomes using the European label for dabigatran , 2013, Thrombosis and Haemostasis.

[16]  H. Sørensen,et al.  Data Resource Profile: The Danish National Prescription Registry , 2016, International journal of epidemiology.

[17]  G. Lip,et al.  Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. , 2013, Journal of the American College of Cardiology.

[18]  J. Tolstrup,et al.  Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study , 2011, BMJ : British Medical Journal.

[19]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[20]  Sigrun Alba Johannesdottir Schmidt,et al.  The Danish National Patient Registry: a review of content, data quality, and research potential , 2015, Clinical epidemiology.

[21]  S. Härtter,et al.  Oral bioavailability of dabigatran etexilate (Pradaxa(®) ) after co-medication with verapamil in healthy subjects. , 2013, British journal of clinical pharmacology.

[22]  Jeroen J. Bax,et al.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. , 2012, European heart journal.